<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Genomics Inform</journal-id>
      <journal-id journal-id-type="iso-abbrev">Genomics Inform</journal-id>
      <journal-id journal-id-type="publisher-id">GNI</journal-id>
      <journal-title-group>
        <journal-title>Genomics &amp; Informatics</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1598-866X</issn>
      <issn pub-type="epub">2234-0742</issn>
      <publisher>
        <publisher-name>Korea Genome Organization</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">27445646</article-id>
      <article-id pub-id-type="pmc">4951399</article-id>
      <article-id pub-id-type="doi">10.5808/GI.2016.14.2.42</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Review Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Ultra-rare Disease and Genomics-Driven Precision Medicine</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Lee</surname>
            <given-names>Sangmoon</given-names>
          </name>
          <xref ref-type="aff" rid="A1"/>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Choi</surname>
            <given-names>Murim</given-names>
          </name>
          <xref ref-type="aff" rid="A1"/>
        </contrib>
      </contrib-group>
      <aff id="A1">Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul 03080, Korea.</aff>
      <author-notes>
        <corresp>Corresponding author: Tel: +82-2-740-8912, Fax: +82-2-3673-2167, <email>murimchoi@snu.ac.kr</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>6</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>30</day>
        <month>6</month>
        <year>2016</year>
      </pub-date>
      <volume>14</volume>
      <issue>2</issue>
      <fpage>42</fpage>
      <lpage>45</lpage>
      <history>
        <date date-type="received">
          <day>31</day>
          <month>7</month>
          <year>2015</year>
        </date>
        <date date-type="rev-recd">
          <day>10</day>
          <month>5</month>
          <year>2016</year>
        </date>
        <date date-type="accepted">
          <day>26</day>
          <month>5</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2016 by the Korea Genome Organization</copyright-statement>
        <copyright-year>2016</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
          <license-p>It is identical to the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>).</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Since next-generation sequencing (NGS) technique was adopted into clinical practices, revolutionary advances in diagnosing rare genetic diseases have been achieved through translating genomic medicine into precision or personalized management. Indeed, several successful cases of molecular diagnosis and treatment with personalized or targeted therapies of rare genetic diseases have been reported. Still, there are several obstacles to be overcome for wider application of NGS-based precision medicine, including high sequencing cost, incomplete variant sensitivity and accuracy, practical complexities, and a shortage of available treatment options.</p>
      </abstract>
      <kwd-group>
        <kwd>next-generation sequencing</kwd>
        <kwd>personalized medicine</kwd>
        <kwd>precision medicine</kwd>
        <kwd>rare disease</kwd>
        <kwd>whole exome sequencing</kwd>
        <kwd>whole genome sequencing</kwd>
      </kwd-group>
      <funding-group>
        <award-group>
          <funding-source country="KR">
            <institution-wrap>
              <institution>Seoul National University</institution>
              <institution-id institution-id-type="CrossRef">http://dx.doi.org/10.13039/501100002551</institution-id>
            </institution-wrap>
          </funding-source>
        </award-group>
      </funding-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>Introduction</title>
      <p>Next-generation sequencing (NGS) has achieved great advances in medicine and clinical practice, as well as in basic research field. NGS-based precision medicine has mainly focused on cancer [<xref rid="B1" ref-type="bibr">1</xref><xref rid="B2" ref-type="bibr">2</xref>], given the prevalence, availability of drugs targeting major oncogenic factors, and impact on human health. Another sector of focus through NGS-based precision medicine is ultra-rare diseases.</p>
      <p>Ultra-rare diseases can be defined as disorders that occur with a prevalence of below 1 in 2,000,000, although this frequency cutoff can be flexible [<xref rid="B3" ref-type="bibr">3</xref>]. Usually, rare disease research is performed with large families for traits with dominant inheritance [<xref rid="B4" ref-type="bibr">4</xref><xref rid="B5" ref-type="bibr">5</xref>] or patient-parent trios for spontaneous cases [<xref rid="B6" ref-type="bibr">6</xref>]. Discovery of causative genetic variants using whole exome sequencing (WES) or whole genome sequencing (WGS) should be followed by <italic>in vitro</italic> or <italic>in vivo</italic> model functional studies to fully explain the molecular basis of the diseases and confirm the functionality of the variants [<xref rid="B4" ref-type="bibr">4</xref><xref rid="B5" ref-type="bibr">5</xref><xref rid="B6" ref-type="bibr">6</xref><xref rid="B7" ref-type="bibr">7</xref>].</p>
      <p>It is presumed that a large portion of ultra-rare diseases are caused by <italic>de novo</italic> mutations occurring at functionally important protein coding regions (<xref ref-type="fig" rid="F1">Fig. 1</xref>) [<xref rid="B8" ref-type="bibr">8</xref>
<xref rid="B9" ref-type="bibr">9</xref>]. Every human zygote is expected to have approximately 70&#x2013;80 <italic>de novo</italic> mutations in its genome, and this poses a small chance to have ultra-rare diseases, depending on the position where the <italic>de novo</italic> mutations lie [<xref rid="B8" ref-type="bibr">8</xref><xref rid="B10" ref-type="bibr">10</xref>].</p>
      <p>Since NGS was adopted into medical genetics, the number of rare disease-causing gene discoveries has been increasing rapidly, and the genetics of many idiopathic diseases have been elucidated [<xref rid="B11" ref-type="bibr">11</xref><xref rid="B12" ref-type="bibr">12</xref><xref rid="B13" ref-type="bibr">13</xref>]. In this review, we present the perspectives gained from recent studies on ultra-rare diseases diagnosed by NGS and successful treatments and discuss the potential obstacles for wider application of NGS-based precision medicine.</p>
    </sec>
    <sec>
      <title>Cystic Fibrosis</title>
      <p>Although cystic fibrosis is not an ultra-rare disease by definition, it presents a good example of precision medicine. Typically inherited in an autosomal recessive manner, patients carry two non-functional alleles of cystic fibrosis transmembrane conductance regulator (<italic>CFTR</italic>). Recently, an NGS-based diagnostic assay to detect mutations in CFTR was authorized for marketing by the United States Food and Drug Administration (FDA) [<xref rid="B14" ref-type="bibr">14</xref>]. In addition, ivacaftor (Kalydeco, Vertex Pharmaceuticals, Cambridge, MA, USA), a potentiator of CFTR, and lumacaftor (Orkambi, Vertex Pharmaceuticals; combination drug with ivacaftor), a corrector of CFTR, were approved by the FDA for the treatment of cystic fibrosis patients with nonsynonymous mutations (<ext-link ext-link-type="uri" xlink:href="http://www.kalydeco.com">http://www.kalydeco.com</ext-link>) and the F508del mutation (<ext-link ext-link-type="uri" xlink:href="http://www.orkambi.com">http://www.orkambi.com</ext-link>), respectively [<xref rid="B15" ref-type="bibr">15</xref>]. NGS-based assays have made it possible to detect certain mutations that can be successfully treated by mutation-specific drugs (<xref ref-type="table" rid="T1">Table 1</xref>) [<xref rid="B16" ref-type="bibr">16</xref>].</p>
    </sec>
    <sec>
      <title>Clinical Practices with NGS-Based Precision Medicine</title>
      <p>The famous case of Nick Volker exemplifies the beneficial effect of NGS techniques on patients with atypical and undiagnosed disorders [<xref rid="B17" ref-type="bibr">17</xref>]. The cause of his fatal bowel inflammation and colocutaneous fistula turned out to be a mutation in the X-linked inhibitor of apoptosis protein (<italic>XIAP</italic>) gene by WES, which has important roles in inflammatory signaling and immunity. His disease was almost cured by cord blood transplantation. Following this, a few more cases of precision medicine supported by NGS have been reported. WGS of 14-year-old twins with dopa (3,4-dihydroxyphenylalanine)-responsive dystonia revealed compound heterozygous mutations in the sepiapterin reductase (<italic>SPR</italic>) gene, encoding sepiapterin reductase. Disruption of the enzyme caused a decrease in the neurotransmitters dopamine and serotonin, and administration of L-dopa with 5-hydroxytryptophan, a serotonin precursor, led to clinical improvements in both twins [<xref rid="B18" ref-type="bibr">18</xref>]. Another case was a cancer: the serine/threonine protein kinase B-raf (<italic>BRAF</italic>) V600E mutation in metastatic rhabdoid meningioma was found by targeted NGS in a 6-year-old girl [<xref rid="B19" ref-type="bibr">19</xref>]. She was successfully treated with dabrafenib, a BRAF inhibitor.</p>
      <p>Most recently, a more dramatic case was of a 14-year-old girl who had suffered from autoimmune enteropathy since she was 3 months old [<xref rid="B6" ref-type="bibr">6</xref>]. A novel <italic>de novo</italic> mutation in the ligand binding domain of cytotoxic T lymphocyte antigen 4 (<italic>CTLA-4</italic>) was discovered by WES (<xref ref-type="fig" rid="F2">Fig. 2</xref>) [<xref rid="B6" ref-type="bibr">6</xref><xref rid="B20" ref-type="bibr">20</xref><xref rid="B21" ref-type="bibr">21</xref>]. The mutation was presumed to be causative after several <italic>in vitro</italic> immunological experiments. Abatacept, an FDA-approved fusion protein of the extracellular domain of CTLA-4 and the Fc region of immunoglobulin for rheumatoid arthritis, was administered to the patient and restored regulatory T cell function. Clinically, treatment with abatacept without the need for other immunosuppressants reduced diarrhea output by about 67% (from 3 L/day to 1 L/day). Markedly, blood transfusion was not necessary anymore, allowing the patient to be discharged from a 3-year-long hospitalization, merely needing partial parenteral nutrition.</p>
    </sec>
    <sec>
      <title>Prenatal Diagnosis</title>
      <p>Prenatal screening and prediction of ultra-rare disease with NGS are not widely used yet due to their cost and efficacy. But, if the parents of a child with an ultra-rare disease who was diagnosed by NGS plan to have another child, prenatal testing with DNA extracted from chorionic villus sampling or amniocentesis is possible. If the cost of NGS declines, screening of rare genetic diseases with NGS might be routinely performed.</p>
      <p>At this moment, a non-invasive prenatal test using NGS is rapidly being introduced to the clinical field, which allows the detection of fetal aneuploidies, such as trisomy 21 (Down syndrome) [<xref rid="B22" ref-type="bibr">22</xref>]. This technique uses cell-free fetal DNA (cffDNA) present in maternal circulation and enables non-invasive liquid biopsy, in contrast to invasive procedures, including amniocentesis and chorionic villus sampling. Although it is technically challenging to detect small nucleotide-level mutations from cffDNA at the present time, extensive research in this field has yielded potential in tackling the problem [<xref rid="B23" ref-type="bibr">23</xref>].</p>
    </sec>
    <sec>
      <title>Obstacles to Precision Medicine and Future Direction</title>
      <p>Despite these encouraging cases, there are wide gaps between the diagnosis and treatment of ultra-rare diseases. Targeted and tailored therapies for ultra-rare diseases are usually hard, mainly because of scarce treatment options. To fill these gaps, several conditions should be fulfilled. First, the cost of NGS should decrease further. As of this writing, the cost of WES has fallen to under USD $1,000, which is still a formidable price for a routine application in clinics, while the usage of WGS may still be impractical. Second, the sensitivity and specificity of genetic diagnostics should be improved. Current commercially available exome capture kits covers ~99% of the RefSeq exome, and over 95% of the targeted bases are covered at least eight times with a typical WES run [<xref rid="B24" ref-type="bibr">24</xref>], implying that we are achieving fair exome coverage technically. However, the positive diagnostic rate of clinical WES for Mendelian phenotypes remains ~30% [<xref rid="B25" ref-type="bibr">25</xref>], suggesting that a substantial portion of the remainder (~70%) might be caused by variants located outside of exons or are not detectable by WES. Although the majority of functionally critical and disease-causing mutations occurs in protein-coding regions, the vast majority of the genome is non-coding and may contain variants with functional significance that has been neglected. Third, processes of NGS data generation should be more simplified. Currently, the typical NGS pipeline consists of library preparation, sequencing, and multiple analysis steps, including read alignments, variant calling, and annotation. For NGS to pervade in clinical practice, the processes from DNA samples to the final results should be more concise. In this context, nanopore sequencing techniques, such as MinION, could function as a good alternative to current NGS technologies if they improve the high error rates and relatively small-scale data output [<xref rid="B26" ref-type="bibr">26</xref>]. Fourth, more treatment options, such as targeted drugs and gene therapy strategies, should be provided. The metastatic rhabdoid meningioma with a BRAF mutation and CTLA-4 cases mentioned above are rather exceptional cases, since the genetic alterations were already targeted through commercially available drugs. Nevertheless, the CTLA-4 case is a good example of drug repositioning, which can be an efficient option to accelerate treatments for ultra-rare diseases, given its shorter development time and lower cost [<xref rid="B27" ref-type="bibr">27</xref>].</p>
    </sec>
    <sec sec-type="conclusions">
      <title>Conclusion</title>
      <p>Although they are given less clinical attention and researched less often, ultra-rare diseases have been occurring constantly, because every new baby will have <italic>de novo</italic> mutations in its genome, posing a small chance of the mutations causing an unseen phenotype. Thus, it would be important to improve prompt and accurate diagnoses and suggest appropriate treatment options for ultra-rare disease patients. Although we still face many technical difficulties to address&#x2014;such as the high price of NGS, imperfect NGS technology, practical complexities, and a shortage of treatment options&#x2014;the several cases illustrated here demonstrate successful application of NGS-based precision medicine for ultra-rare diseases, benefiting patient care in the long term. In the near future, NGS will be an essential component in precision medicine regarding its high throughput and relatively low and further decreasing cost and the importance of individual genomic information for personalized strategies.</p>
    </sec>
  </body>
  <back>
    <ack>
      <title>Acknowledgments</title>
      <p>This work was supported by a Research Resettlement Fund for new faculty of Seoul National University.</p>
    </ack>
    <ref-list>
      <ref id="B1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hagemann</surname>
              <given-names>IS</given-names>
            </name>
            <name>
              <surname>Cottrell</surname>
              <given-names>CE</given-names>
            </name>
            <name>
              <surname>Lockwood</surname>
              <given-names>CM</given-names>
            </name>
          </person-group>
          <article-title>Design of targeted, capture-based, next generation sequencing tests for precision cancer therapy</article-title>
          <source>Cancer Genet</source>
          <year>2013</year>
          <volume>206</volume>
          <fpage>420</fpage>
          <lpage>431</lpage>
          <pub-id pub-id-type="pmid">24388712</pub-id>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yadav</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Lavery</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Yadav</surname>
              <given-names>KK</given-names>
            </name>
            <name>
              <surname>Tewari</surname>
              <given-names>AK</given-names>
            </name>
          </person-group>
          <article-title>Next-generation sequencing technology in prostate cancer diagnosis, prognosis, and personalized treatment</article-title>
          <source>Urol Oncol</source>
          <year>2015</year>
          <volume>33</volume>
          <fpage>267.e1</fpage>
          <lpage>267.e13</lpage>
          <pub-id pub-id-type="pmid">25791755</pub-id>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hennekam</surname>
              <given-names>RC</given-names>
            </name>
          </person-group>
          <article-title>Care for patients with ultra-rare disorders</article-title>
          <source>Eur J Med Genet</source>
          <year>2011</year>
          <volume>54</volume>
          <fpage>220</fpage>
          <lpage>224</lpage>
          <pub-id pub-id-type="pmid">21147279</pub-id>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mencacci</surname>
              <given-names>NE</given-names>
            </name>
            <name>
              <surname>Rubio-Agusti</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Zdebik</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Asmus</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Ludtmann</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Ryten</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A missense mutation in <italic>KCTD17</italic> causes autosomal dominant myoclonus-dystonia</article-title>
          <source>Am J Hum Genet</source>
          <year>2015</year>
          <volume>96</volume>
          <fpage>938</fpage>
          <lpage>947</lpage>
          <pub-id pub-id-type="pmid">25983243</pub-id>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zech</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lam</surname>
              <given-names>DD</given-names>
            </name>
            <name>
              <surname>Francescatto</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Schormair</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Salminen</surname>
              <given-names>AV</given-names>
            </name>
            <name>
              <surname>Jochim</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Recessive mutations in the &#x3B1;3 (VI) collagen gene <italic>COL6A3</italic> cause early-onset isolated dystonia</article-title>
          <source>Am J Hum Genet</source>
          <year>2015</year>
          <volume>96</volume>
          <fpage>883</fpage>
          <lpage>893</lpage>
          <pub-id pub-id-type="pmid">26004199</pub-id>
        </element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Moon</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>HE</given-names>
            </name>
            <name>
              <surname>Baek</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Hwang</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Abatacept alleviates severe autoimmune symptoms in a patient carrying a <italic>de novo</italic> variant in CTLA-4</article-title>
          <source>J Allergy Clin Immunol</source>
          <year>2016</year>
          <volume>137</volume>
          <fpage>327</fpage>
          <lpage>330</lpage>
          <pub-id pub-id-type="pmid">26478010</pub-id>
        </element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mousallem</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Urban</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>McSweeney</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Kleinstein</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Zhu</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Adeli</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Clinical application of whole-genome sequencing in patients with primary immunodeficiency</article-title>
          <source>J Allergy Clin Immunol</source>
          <year>2015</year>
          <volume>136</volume>
          <fpage>476</fpage>
          <lpage>479.e6</lpage>
          <pub-id pub-id-type="pmid">25981738</pub-id>
        </element-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Veltman</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Brunner</surname>
              <given-names>HG</given-names>
            </name>
          </person-group>
          <article-title><italic>De novo</italic> mutations in human genetic disease</article-title>
          <source>Nat Rev Genet</source>
          <year>2012</year>
          <volume>13</volume>
          <fpage>565</fpage>
          <lpage>575</lpage>
          <pub-id pub-id-type="pmid">22805709</pub-id>
        </element-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <element-citation publication-type="journal">
          <collab>Deciphering Developmental Disorders Study</collab>
          <article-title>Large-scale discovery of novel genetic causes of developmental disorders</article-title>
          <source>Nature</source>
          <year>2015</year>
          <volume>519</volume>
          <fpage>223</fpage>
          <lpage>228</lpage>
          <pub-id pub-id-type="pmid">25533962</pub-id>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rahbari</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Wuster</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lindsay</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Hardwick</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Alexandrov</surname>
              <given-names>LB</given-names>
            </name>
            <name>
              <surname>Al Turki</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Timing, rates and spectra of human germline mutation</article-title>
          <source>Nat Genet</source>
          <year>2016</year>
          <volume>48</volume>
          <fpage>126</fpage>
          <lpage>133</lpage>
          <pub-id pub-id-type="pmid">26656846</pub-id>
        </element-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Boycott</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Vanstone</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Bulman</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>MacKenzie</surname>
              <given-names>AE</given-names>
            </name>
          </person-group>
          <article-title>Rare-disease genetics in the era of next-generation sequencing: discovery to translation</article-title>
          <source>Nat Rev Genet</source>
          <year>2013</year>
          <volume>14</volume>
          <fpage>681</fpage>
          <lpage>691</lpage>
          <pub-id pub-id-type="pmid">23999272</pub-id>
        </element-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Choi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Scholl</surname>
              <given-names>UI</given-names>
            </name>
            <name>
              <surname>Ji</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Tikhonova</surname>
              <given-names>IR</given-names>
            </name>
            <name>
              <surname>Zumbo</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Genetic diagnosis by whole exome capture and massively parallel DNA sequencing</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>2009</year>
          <volume>106</volume>
          <fpage>19096</fpage>
          <lpage>19101</lpage>
          <pub-id pub-id-type="pmid">19861545</pub-id>
        </element-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Seo</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Choi</surname>
              <given-names>IH</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Yoo</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>NK</given-names>
            </name>
            <name>
              <surname>Choi</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Rare cases of congenital arthrogryposis multiplex caused by novel recurrent <italic>CHRNG</italic> mutations</article-title>
          <source>J Hum Genet</source>
          <year>2015</year>
          <volume>60</volume>
          <fpage>213</fpage>
          <lpage>215</lpage>
          <pub-id pub-id-type="pmid">25608830</pub-id>
        </element-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Grosu</surname>
              <given-names>DS</given-names>
            </name>
            <name>
              <surname>Hague</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Chelliserry</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kruglyak</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Lenta</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Klotzle</surname>
              <given-names>B</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Clinical investigational studies for validation of a next-generation sequencing <italic>in vitro</italic> diagnostic device for cystic fibrosis testing</article-title>
          <source>Expert Rev Mol Diagn</source>
          <year>2014</year>
          <volume>14</volume>
          <fpage>605</fpage>
          <lpage>622</lpage>
          <pub-id pub-id-type="pmid">24844137</pub-id>
        </element-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kuk</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Taylor-Cousar</surname>
              <given-names>JL</given-names>
            </name>
          </person-group>
          <article-title>Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects</article-title>
          <source>Ther Adv Respir Dis</source>
          <year>2015</year>
          <volume>9</volume>
          <fpage>313</fpage>
          <lpage>326</lpage>
          <pub-id pub-id-type="pmid">26416827</pub-id>
        </element-citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rogan</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Stoltz</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Hornick</surname>
              <given-names>DB</given-names>
            </name>
          </person-group>
          <article-title>Cystic fibrosis transmembrane conductance regulator intracellular processing, trafficking, and opportunities for mutation-specific treatment</article-title>
          <source>Chest</source>
          <year>2011</year>
          <volume>139</volume>
          <fpage>1480</fpage>
          <lpage>1490</lpage>
          <pub-id pub-id-type="pmid">21652558</pub-id>
        </element-citation>
      </ref>
      <ref id="B17">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Worthey</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Mayer</surname>
              <given-names>AN</given-names>
            </name>
            <name>
              <surname>Syverson</surname>
              <given-names>GD</given-names>
            </name>
            <name>
              <surname>Helbling</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Bonacci</surname>
              <given-names>BB</given-names>
            </name>
            <name>
              <surname>Decker</surname>
              <given-names>B</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Making a definitive diagnosis: successful clinical application of whole exome sequencing in a child with intractable inflammatory bowel disease</article-title>
          <source>Genet Med</source>
          <year>2011</year>
          <volume>13</volume>
          <fpage>255</fpage>
          <lpage>262</lpage>
          <pub-id pub-id-type="pmid">21173700</pub-id>
        </element-citation>
      </ref>
      <ref id="B18">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bainbridge</surname>
              <given-names>MN</given-names>
            </name>
            <name>
              <surname>Wiszniewski</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Murdock</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Friedman</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Gonzaga-Jauregui</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Newsham</surname>
              <given-names>I</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Whole-genome sequencing for optimized patient management</article-title>
          <source>Sci Transl Med</source>
          <year>2011</year>
          <volume>3</volume>
          <fpage>87re3</fpage>
        </element-citation>
      </ref>
      <ref id="B19">
        <label>19</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mordechai</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Postovsky</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Vlodavsky</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Eran</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Constantini</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Dotan</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Metastatic rhabdoid meningioma with <italic>BRAF</italic> V600E mutation and good response to personalized therapy: case report and review of the literature</article-title>
          <source>Pediatr Hematol Oncol</source>
          <year>2015</year>
          <volume>32</volume>
          <fpage>207</fpage>
          <lpage>211</lpage>
          <pub-id pub-id-type="pmid">25116269</pub-id>
        </element-citation>
      </ref>
      <ref id="B20">
        <label>20</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yu</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Sonnen</surname>
              <given-names>AF</given-names>
            </name>
            <name>
              <surname>George</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Dessailly</surname>
              <given-names>BH</given-names>
            </name>
            <name>
              <surname>Stagg</surname>
              <given-names>LJ</given-names>
            </name>
            <name>
              <surname>Evans</surname>
              <given-names>EJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Rigid-body ligand recognition drives cytotoxic T-lymphocyte antigen 4 (CTLA-4) receptor triggering</article-title>
          <source>J Biol Chem</source>
          <year>2011</year>
          <volume>286</volume>
          <fpage>6685</fpage>
          <lpage>6696</lpage>
          <pub-id pub-id-type="pmid">21156796</pub-id>
        </element-citation>
      </ref>
      <ref id="B21">
        <label>21</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stamper</surname>
              <given-names>CC</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Tobin</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Erbe</surname>
              <given-names>DV</given-names>
            </name>
            <name>
              <surname>Ikemizu</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Davis</surname>
              <given-names>SJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses</article-title>
          <source>Nature</source>
          <year>2001</year>
          <volume>410</volume>
          <fpage>608</fpage>
          <lpage>611</lpage>
          <pub-id pub-id-type="pmid">11279502</pub-id>
        </element-citation>
      </ref>
      <ref id="B22">
        <label>22</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nepomnyashchaya</surname>
              <given-names>YN</given-names>
            </name>
            <name>
              <surname>Artemov</surname>
              <given-names>AV</given-names>
            </name>
            <name>
              <surname>Roumiantsev</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Roumyantsev</surname>
              <given-names>AG</given-names>
            </name>
            <name>
              <surname>Zhavoronkov</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Non-invasive prenatal diagnostics of aneuploidy using next-generation DNA sequencing technologies, and clinical considerations</article-title>
          <source>Clin Chem Lab Med</source>
          <year>2013</year>
          <volume>51</volume>
          <fpage>1141</fpage>
          <lpage>1154</lpage>
          <pub-id pub-id-type="pmid">23023923</pub-id>
        </element-citation>
      </ref>
      <ref id="B23">
        <label>23</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>St&#xE5;hlberg</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Krzyzanowski</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Jackson</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Egyud</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Stein</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Godfrey</surname>
              <given-names>TE</given-names>
            </name>
          </person-group>
          <article-title>Simple, multiplexed, PCR-based barcoding of DNA enables sensitive mutation detection in liquid biopsies using sequencing</article-title>
          <source>Nucleic Acids Res</source>
          <year>2016</year>
          <volume>44</volume>
          <fpage>e105</fpage>
          <pub-id pub-id-type="pmid">27060140</pub-id>
        </element-citation>
      </ref>
      <ref id="B24">
        <label>24</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lim</surname>
              <given-names>BC</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>Hwang</surname>
              <given-names>YS</given-names>
            </name>
            <name>
              <surname>Choi</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Alpha-thalassemia X-linked intellectual disability syndrome identified by whole exome sequencing in two boys with white matter changes and developmental retardation</article-title>
          <source>Gene</source>
          <year>2015</year>
          <volume>569</volume>
          <fpage>318</fpage>
          <lpage>322</lpage>
          <pub-id pub-id-type="pmid">25936994</pub-id>
        </element-citation>
      </ref>
      <ref id="B25">
        <label>25</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chong</surname>
              <given-names>JX</given-names>
            </name>
            <name>
              <surname>Buckingham</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>Jhangiani</surname>
              <given-names>SN</given-names>
            </name>
            <name>
              <surname>Boehm</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Sobreira</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>JD</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The genetic basis of Mendelian phenotypes: discoveries, challenges, and opportunities</article-title>
          <source>Am J Hum Genet</source>
          <year>2015</year>
          <volume>97</volume>
          <fpage>199</fpage>
          <lpage>215</lpage>
          <pub-id pub-id-type="pmid">26166479</pub-id>
        </element-citation>
      </ref>
      <ref id="B26">
        <label>26</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Quick</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ashton</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Calus</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Chatt</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Gossain</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hawker</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Rapid draft sequencing and real-time nanopore sequencing in a hospital outbreak of Salmonella</article-title>
          <source>Genome Biol</source>
          <year>2015</year>
          <volume>16</volume>
          <fpage>114</fpage>
          <pub-id pub-id-type="pmid">26025440</pub-id>
        </element-citation>
      </ref>
      <ref id="B27">
        <label>27</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>YY</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>SJ</given-names>
            </name>
          </person-group>
          <article-title>Drug repositioning for personalized medicine</article-title>
          <source>Genome Med</source>
          <year>2012</year>
          <volume>4</volume>
          <fpage>27</fpage>
          <pub-id pub-id-type="pmid">22494857</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="F1" orientation="portrait" position="float">
      <label>Fig. 1</label>
      <caption>
        <title>Mode of inheritance of rare genetic diseases that were definitively diagnosed in a cohort of developmental disorders. Drawn with data adopted from Deciphering Developmental Disorders Study. <italic>Nature</italic> 2015;519:223-228 [<xref rid="B9" ref-type="bibr">9</xref>].</title>
      </caption>
      <graphic xlink:href="gni-14-42-g001"/>
    </fig>
    <fig id="F2" orientation="portrait" position="float">
      <label>Fig. 2</label>
      <caption>
        <title><italic>De novo</italic> mutation in ligand binding motif of cytotoxic T lymphocyte antigen 4 (CTLA-4). Modified from Lee <italic>et al</italic>. J Allergy Clin Immunol 2016;137:327-330 [<xref rid="B6" ref-type="bibr">6</xref>]. (A) Proband-specific <italic>de novo</italic> mutation in <italic>CTLA-4</italic> shown in the pedigree. (B) Crystal structure of CTLA-4 homodimer (right) (Protein Data Bank [PDB] ID: 3OSK) [<xref rid="B20" ref-type="bibr">20</xref>] and close-up view of interaction between CTLA-4 and CD80 (left) (PDB ID: 1I8L) [<xref rid="B21" ref-type="bibr">21</xref>]. (C) Models of mutant CTLA-4 failing to bind to CD80/CD86 and regulate immune reactions and rescued by CTLA-4-Ig (abatacept). APC, antigen-presenting cell; Th cell, T helper cell.</title>
      </caption>
      <graphic xlink:href="gni-14-42-g002"/>
    </fig>
    <table-wrap id="T1" orientation="portrait" position="float">
      <label>Table 1</label>
      <caption>
        <title>Classes of <italic>CFTR</italic> mutations</title>
      </caption>
      <graphic xlink:href="gni-14-42-i001"/>
      <table-wrap-foot>
        <fn>
          <p>CFTR, cystic fibrosis transmembrane conductance regulator.</p>
          <p>Modified from Rogan <italic>et al</italic>. <italic>Chest</italic> 2011;139:1480-1490 [<xref rid="B16" ref-type="bibr">16</xref>], with permission of Elsevier (License Number: 3892970032119).</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
  </floats-group>
</article>
</pmc-articleset>